Connect with us

Headlines

Pharma Company with Eyecare Focus Names CEO

He previously served as interim chief.

mm

Published

on

EMERYVILLE, CA — NovaBay Pharmaceuticals Inc., a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, announces the appointments of Justin Hall as president and CEO and Jason Raleigh as chief financial officer.

Hall has served as interim president and CEO, and Raleigh as interim CFO, since March 2019.

“Justin and Jason have proven their leadership abilities by successfully implementing the shift in our U.S. commercial strategy we announced in March and executing the recent launch of our U.S. direct-to-consumer sales of Avenova on Amazon.com,” said Paul E. Freiman, chairman of NovaBay.

“This is a very exciting time at NovaBay as we launch Avenova Direct, making our leading lid and lash spray directly accessible to consumers without a prescription and at affordable pricing,” Hall said. “My close working relationships with our Board, principal investors, and sales force are key to quickly adjusting our strategy to rapidly address opportunities in the marketplace. We are on the move and we have momentum.”

Advertisement

Raleigh said: “I’m honored to be selected as CFO and appreciate the Board’s trust in my abilities. I look forward to continuing to work with Justin and the NovaBay team toward the continued successful commercialization of Avenova.”

Hall has served with NovaBay for six years in a variety of roles, including as corporate counsel, and has been actively involved in a number of operating functions, including the sales organization and manufacturing. Raleigh has been with NovaBay for more than three years and has nearly 20 years of financial experience.

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at editor@invisionmag.com.

Advertisement

SPONSORED VIDEO

SPONSORED BY REICHERT

When You’re Passionate About Eye Care, the Right Technology Matters

Lisa Genovese, O.D., strives to give her patients the very best. At Insight Eye Care’s multiple locations, Dr. Genovese provides optimal care for her patients using the Reichert® Phoroptor® VRx Digital Refraction System. In this second Practice Profile Video from Reichert’s “Passionate About Eye Care” series, take a closer look and see how this eye care professional achieved a better work-life balance with equipment that’s designed and engineered in the U.S.A.

Promoted Headlines

Headlines

Smart Glasses ‘Breakthrough’ Likely Not Far Off, Zuckerberg Says

New products ‘will redefine our relationship with technology.’

mm

Published

on

Facebook CEO Mark Zuckerberg says major developments in augmented reality are probable in the coming decade, CNBC reports.

He offered his thoughts in a Facebook post last week, writing, “The technology platform of the 2010s was the mobile phone. While I expect phones to still be our primary devices through most of this decade, at some point in the 2020s, we will get breakthrough augmented reality glasses that will redefine our relationship with technology.”

CNBC decribes augmented reality as “technology that lets users place digital objects on top of the real world.”

Zuckerberg acknowledged that some augmented-reality products to this point have felt “clunky.” But he said new products “will be the most human and social technology platforms anyone has built yet.”

He said augmented reality could improve many areas of life, including careers: “Imagine if you could live anywhere you chose and access any job anywhere else. If we deliver on what we’re building, this should be much closer to reality by 2030.”

In September, Facebook was reported to be working with Luxottica to develop a pair of smart glasses. The project was reportedly code-named Orion.

Advertisement

The glasses would be intended to disrupt the smartphone market. Zacks reported at the time that the idea was to “allow users of the smart glasses to take calls, livestream on social media and many other such features that are intended to replace smartphones.”

With the smart glasses project, Facebook was apparently “raising its efforts to withstand the intense competition in the next-generation glasses space from Snap, Google, Microsoft and Apple,” Zacks said at the time.

Read more at the CNBC

Continue Reading

Headlines

$60M to Support Potential Treatment for Eyelash Mite Outbreaks

It could be the ‘first-ever drug treatment for this condition.’

mm

Published

on

IRVINE, CA — Tarsus Pharmaceuticals has announced the completion of $60 million in Series B financing.

The clinical-stage biopharmaceutical company will use the funds to start a Phase 2b/3 trial in the U.S. of its lead product, a drug candidate for treatment of Demodex blepharitis.

An estimated 20 million Americans suffer from blepharitis, and approximately 45 percent of them have clinical signs of Demodex mites, the company explains in a press release. Tarsus is developing a topical ophthalmic that “targets an underlying cause of blepharitis and has the potential to be the first-ever drug treatment for this condition,” according to the release.

The funding will also fuel Phase 1 and 2 development of other clinical programs. The company’s product pipeline includes additional indications in eyecare and other areas of high unmet clinical need, according to the release.

“We’re excited to support this innovative company that is developing the first drug for Demodex blepharitis and building a pipeline of products to address other large market opportunities,” said Dr. Chen Yu, managing partner at Vivo Capital.

Michael Ackermann, Tarsus chairman, said, “We founded Tarsus with the mission of bringing to market the first drug for Demodex blepharitis, an important unmet need and one of the largest diseases in anterior segment medicine.”

Dr. Bobby Azamian, Tarsus CEO, added, “We are grateful for support from a leading syndicate of healthcare investors. This financing will allow Tarsus to grow, conduct a first registration study in Demodex blepharitis, and broaden our mission to deliver innovative therapies in eye care and beyond by advancing our clinical pipeline in 2020.”

The financing was led by Vivo Capital and included Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners and Horowitz Group.

 

Continue Reading

Headlines

California’s Medi-Cal Puts Eyeglasses Back on List of Covered Services

They were cut several years ago.

mm

Published

on

California’s Medicaid program, Medi-Cal, has restored eyeglasses to its list of covered services.

Eyeglasses were cut several years ago as California adjusted to the recession, leaving adults on the program to pay for them out of pocket, Central Coast Public Radio reports.

Capital Public Radio notes that vision exams and other eye health services have continued to be covered.

“We want everyone to see, and we think everyone deserves to see,” Dr. David Ardaya of the California Optometric Association said, acccording to Central Coast Public Radio.

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?
INVISION Podcast

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?
INVISION Podcast

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries
INVISION Podcast

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries

Contact lenses still will not be covered.

Medi-Cal is also restoring coverage for certain other services, such as podiatry and speech therapy.

Read more at the Central Coast Public Radio

Continue Reading

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular